Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10051895 | The Journal of Urology | 2005 | 4 Pages |
Abstract
The low risk of systemic relapse in patients with PS I and PN1 after RPLND alone combined with the 16% incidence of retroperitoneal teratoma and the favorable morbidity profile supports RPLND over primary chemotherapy for the treatment of patients with low stage disease with ECP and/or LVI who are not candidates for surveillance. An estimated 72% of patients are spared the potential toxicity of chemotherapy if adjuvant therapy is restricted to patients with PN2. After primary RPLND and selective adjuvant chemotherapy late recurrence is distinctly uncommon and long-term cancer control is anticipated in essentially all patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
ANDREW J. STEPHENSON, GEORGE J. BOSL, DEAN F. BAJORIN, JASON STASI, ROBERT J. MOTZER, JOEL SHEINFELD,